Ripple Therapeutics Corporation

Ripple Therapeutics Corporation is a clinical-stage ophthalmic therapeutics company focused on developing innovative sustained drug delivery systems for ocular diseases. Founded in 2020, Ripple Therapeutics Corporation operates out of Toronto, Canada, and specializes in ophthalmic therapeutics. The company raised USD 14. 8 mn in a Series A funding round on December 15, 2020, led by Théa Open Innovation with additional investment from the Business Development Bank of Canada.

Ripple has completed one deal to date. Ripple Therapeutics is dedicated to developing sustained drug delivery systems through its proprietary Epidel™ platform, which allows for the creation of implantable drug delivery forms like cylinders and microspheres. These products are specifically aimed at treating ocular conditions including retinal vein occlusion (RVO), diabetic macular edema (DME), and glaucoma, targeting healthcare providers such as ophthalmologists. While headquartered in Toronto, the company intends for its products to reach broader markets across North America and beyond as they progress in clinical development.

Ripple Therapeutics has established a revenue model through strategic partnerships and licensing agreements with major pharmaceutical companies. The company has notably collaborated with AbbVie for the development of the RTC-620 implant targeting open-angle glaucoma and ocular hypertension, receiving an upfront payment and potential milestone payments as part of this agreement. Ripple’s sales strategy is primarily business-to-business, engaging with pharmaceutical companies rather than direct consumer sales, with specific pricing and revenue details undisclosed. Ripple Therapeutics plans to utilize the USD 14.

8 mn raised in its latest funding to advance its product development and clinical trials. The company is focused on launching its RTC-620 implant for open-angle glaucoma and aims to expand into additional markets throughout North America and potentially other regions. As part of its growth strategy, Ripple is exploring further collaborations and partnerships to enhance its extended-release prodrug technology, aiming for continued development and commercialization of its innovative therapies.